Cargando…

Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice

INTRODUCTION: The effectiveness of single-inhaler budesonide/formoterol fumarate combination therapy for asthma has been previously shown for the original product. The aim of this nonrandomized, open-label, postauthorization efficacy study (PAES) real-life clinical assessment was to evaluate the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirożyński, Michał, Hantulik, Piotr, Almgren-Rachtan, Agnieszka, Chudek, Jerzy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709454/
https://www.ncbi.nlm.nih.gov/pubmed/29119403
http://dx.doi.org/10.1007/s12325-017-0641-5
_version_ 1783282780894920704
author Pirożyński, Michał
Hantulik, Piotr
Almgren-Rachtan, Agnieszka
Chudek, Jerzy
author_facet Pirożyński, Michał
Hantulik, Piotr
Almgren-Rachtan, Agnieszka
Chudek, Jerzy
author_sort Pirożyński, Michał
collection PubMed
description INTRODUCTION: The effectiveness of single-inhaler budesonide/formoterol fumarate combination therapy for asthma has been previously shown for the original product. The aim of this nonrandomized, open-label, postauthorization efficacy study (PAES) real-life clinical assessment was to evaluate the clinical effectiveness of a second product (Bufomix Easyhaler(®)) in the daily clinical practice of asthma therapy. METHODS: This multicenter PAES was conducted by 220 unselected allergologists and pulmonologists who enrolled 2200 adult outpatients (age 49.8 ± 17.9 years) with asthma treated with Bufomix Easyhaler(®) for at least 14 days before enrolment. Asthma control was assessed during three subsequent visits with 8–12-week intervals on the basis of the Asthma Control Test (ACT). Adherence was assessed with the Medication Adherence Questionnaire. In addition, patient satisfaction with Bufomix Easyhaler(®) was scored, and adverse drug reactions were recorded. RESULTS: The percentage of patients with well-controlled asthma or total control of asthma (ACT score 20-25 points) increased from 46.6% at the first visit to 90.8% at the third visit (p < 0.001). In addition, the percentage of patients with poor control of asthma (ACT score less than 15 points) decreased from 14.9% to 1.2% (p < 0.001). The adherence rate increased from 88% at the first visit to 95.3% at the third visit. Patient satisfaction with the use of this dry powder inhaler increased with the duration of its use. Only one adverse drug reaction was reported. CONCLUSION: The results obtained confirm the effectiveness of Bufomix Easyhaler(®) in the treatment of asthma in outpatient adults in daily clinical practice. FUNDING: Orion Corporation
format Online
Article
Text
id pubmed-5709454
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-57094542017-12-06 Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice Pirożyński, Michał Hantulik, Piotr Almgren-Rachtan, Agnieszka Chudek, Jerzy Adv Ther Original Research INTRODUCTION: The effectiveness of single-inhaler budesonide/formoterol fumarate combination therapy for asthma has been previously shown for the original product. The aim of this nonrandomized, open-label, postauthorization efficacy study (PAES) real-life clinical assessment was to evaluate the clinical effectiveness of a second product (Bufomix Easyhaler(®)) in the daily clinical practice of asthma therapy. METHODS: This multicenter PAES was conducted by 220 unselected allergologists and pulmonologists who enrolled 2200 adult outpatients (age 49.8 ± 17.9 years) with asthma treated with Bufomix Easyhaler(®) for at least 14 days before enrolment. Asthma control was assessed during three subsequent visits with 8–12-week intervals on the basis of the Asthma Control Test (ACT). Adherence was assessed with the Medication Adherence Questionnaire. In addition, patient satisfaction with Bufomix Easyhaler(®) was scored, and adverse drug reactions were recorded. RESULTS: The percentage of patients with well-controlled asthma or total control of asthma (ACT score 20-25 points) increased from 46.6% at the first visit to 90.8% at the third visit (p < 0.001). In addition, the percentage of patients with poor control of asthma (ACT score less than 15 points) decreased from 14.9% to 1.2% (p < 0.001). The adherence rate increased from 88% at the first visit to 95.3% at the third visit. Patient satisfaction with the use of this dry powder inhaler increased with the duration of its use. Only one adverse drug reaction was reported. CONCLUSION: The results obtained confirm the effectiveness of Bufomix Easyhaler(®) in the treatment of asthma in outpatient adults in daily clinical practice. FUNDING: Orion Corporation Springer Healthcare 2017-11-08 2017 /pmc/articles/PMC5709454/ /pubmed/29119403 http://dx.doi.org/10.1007/s12325-017-0641-5 Text en © The Author(s) 2017 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Pirożyński, Michał
Hantulik, Piotr
Almgren-Rachtan, Agnieszka
Chudek, Jerzy
Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice
title Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice
title_full Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice
title_fullStr Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice
title_full_unstemmed Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice
title_short Evaluation of the Efficiency of Single-Inhaler Combination Therapy with Budesonide/Formoterol Fumarate in Patients with Bronchial Asthma in Daily Clinical Practice
title_sort evaluation of the efficiency of single-inhaler combination therapy with budesonide/formoterol fumarate in patients with bronchial asthma in daily clinical practice
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709454/
https://www.ncbi.nlm.nih.gov/pubmed/29119403
http://dx.doi.org/10.1007/s12325-017-0641-5
work_keys_str_mv AT pirozynskimichał evaluationoftheefficiencyofsingleinhalercombinationtherapywithbudesonideformoterolfumarateinpatientswithbronchialasthmaindailyclinicalpractice
AT hantulikpiotr evaluationoftheefficiencyofsingleinhalercombinationtherapywithbudesonideformoterolfumarateinpatientswithbronchialasthmaindailyclinicalpractice
AT almgrenrachtanagnieszka evaluationoftheefficiencyofsingleinhalercombinationtherapywithbudesonideformoterolfumarateinpatientswithbronchialasthmaindailyclinicalpractice
AT chudekjerzy evaluationoftheefficiencyofsingleinhalercombinationtherapywithbudesonideformoterolfumarateinpatientswithbronchialasthmaindailyclinicalpractice